Tesamorelin

Tesamorelin – Benefits & Side Effects

Tesamorelin – Protocol

Tesamorelin – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

Tesamorelin – Identification

Common Name(s): Tesamorelin, Tesamorelin acetate, Growth Hormone-Releasing Hormone (1-44) amide, GHRH(1-44), TH9507, Somatoliberin (modified)

Trade Names (Approved Products): Egrifta (original formulation, approved October 2010); Egrifta SV (sustained-release formulation, approved November 2019)

CAS Number: 218949-48-5 (free base); 901758-09-6 (acetate salt)

Molecular Formula (Free Base): C₂₂₁H₃₆₆N₇₂O₆₇S

Molecular Weight: 5135.86 Da (free base); approximately 5579 Da (acetate salt with ~7.4 acetate counter ions per molecule)

Origin & Type Classification:

• Source: Synthetic; derived from human GHRH sequence but not naturally occurring

• Biosynthesis: Nonribosomal synthetic peptide manufactured by solid-phase peptide synthesis

• Functional Class: Growth hormone secretagogue, GHRH receptor agonist, pituitary hormone-stimulating peptide

Amino Acid Sequence (44 amino acids):

Complete Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂

Single-Letter Code: YADAIFTNSYRKR VLGQLSARKLAQDIMSRQQGESQGERGARARLNH₂

Key Structural Features:

• Structural Type: Linear 44-amino acid peptide chain, amidated at C-terminus

• N-Terminal Modification: trans-3-hexenoic acid moiety (C6 chain with double bond at position 3 between carbons 3-4) conjugated to the amino group of Tyr1 via an amide linkage, enhancing receptor binding affinity and markedly increasing resistance to peptidase cleavage

• Homology: Identical in primary amino acid sequence to human somatoliberin (GHRH) except for the N-terminal lipid modification

• Peptide Length: 44 amino acids, matching the complete length of native GHRH (unlike some shorter GHRH analogs that truncate the C-terminal region)

Physical Properties:

• Physical Form: White to off-white lyophilized (freeze-dried) powder or film

• Solubility: Soluble in water at physiological pH; slightly soluble in organic solvents (methanol)

• Storage Conditions: Store at 2–8°C (36–46°F) in original carton protected from light; do not freeze; shelf life approximately 21 days after reconstitution

• Stability: Enhanced resistance to dipeptidyl peptidase-IV (DPP-IV) and other serum peptidases compared to native GHRH; the trans-3-hexenoic acid N-terminal modification is primarily responsible for this increased proteolytic stability

Pharmacokinetic Parameters:

• Absolute Bioavailability: Less than 4% following subcutaneous administration

• Absorption: Rapid, with peak plasma concentrations reached within hours of injection

• Elimination Half-life: 8–26 minutes in healthy subjects; 38 minutes in HIV-infected patients (mean values reported variably as 8–11 minutes acutely, potentially increasing slightly with continued dosing)

• Volume of Distribution: 4.8 ± 1.9 L/kg after 1.28 mg dose

• Metabolism: Undergoes proteolytic cleavage of the peptide backbone by serum peptidases and potentially local tissue proteases; the N-terminal hexenoyl moiety may undergo β-oxidation. Limited human metabolism data available; no formal human metabolism studies documented

• Elimination Route: Primary route presumed to be proteolytic degradation; exact elimination pathways not fully characterized in humans

• Clearance: Clearance rate approximately 0.58 L/kg/hour (for reference, implying rapid elimination despite extended residence time through repeated dosing)

Receptor Binding and Pharmacodynamics:

• GHRH Receptor Affinity: The trans-3-hexenoic acid N-terminal modification results in binding affinity to GHRH receptors comparable to or slightly exceeding that of native human GHRH

• Mechanism of Action: Agonist at GHRH receptor (a type-2/class B secretin-like G-protein coupled receptor) on anterior pituitary somatotroph cells, stimulating synthesis and pulsatile release of endogenous growth hormone

• G-Protein Signaling: Activates Gs-coupled G-protein signaling cascade, increasing intracellular cyclic adenosine monophosphate (cAMP) and downstream calcium signaling

Salt Forms & Formulations:

Tesamorelin is supplied as the acetate salt in pharmaceutical formulations. Both the original Egrifta and newer Egrifta SV formulations contain lyophilized tesamorelin acetate powder (1 mg or 2 mg per vial) with reconstitution instructions. The acetate salt provides stability during manufacturing, storage, and reconstitution while maintaining the bioactive form of tesamorelin upon administration.

Synonyms in Literature:

• Growth hormone-releasing factor (1-44) amide

• GHRH(1-44) analogue

• Somatoliberin analogue

• GH secretagogue

• TH-9507 (development code)

Database Links & Identifiers:

• PubChem CID: 16137828 (free base); 146681838 (alternative entry)

• DrugBank ID: DB08869

• UniProt: Q02643 (GHRH receptor in humans)

• HMDB ID: HMDB0259623

• FDA UNII: MQG94M5EEO

• NCI Thesaurus Code: C77425

• KEGG Drug ID: Not separately listed (component of GHRH pathway information)

Tesamorelin – Research

Tesamorelin is a lab-made copy of growth hormone-releasing hormone (GHRH), the natural messenger your brain sends to the pituitary gland saying "make growth hormone!" It's designed like GHRH with an extra fat tail that keeps it in your blood longer—up to 6-8 days instead of just minutes. Growth hormone tells your body to build muscle, burn fat, and stay energetic. HIV patients on medications often get extra belly fat that won't go away with diet and exercise; Tesamorelin fixes this. It shrinks deep belly fat (visceral fat around organs) without touching safe fat under skin, improves cholesterol, boosts energy and mood, and keeps your muscles strong. Studies show it works for 52 weeks straight, and is safe even for people with blood sugar concerns.

Study: Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials
Benefits: Shrinks belly fat 24% in 6 months, lowers triglycerides and cholesterol, improves how people feel about their body, safe on blood sugar.
Link: https://pubmed.ncbi.nlm.nih.gov/20554713/
Summary: 806 HIV patients on meds got daily Tesamorelin 2mg or placebo shots. After 26 weeks, belly fat dropped 24% (versus plus 2% for placebo), with triglycerides down 37 mg/dL vs slight rise for others. Cholesterol and belly appearance both improved big-time. A year in, fat loss held steady at 17.5% below baseline, waist thinner by 3.4 cm. Regular under-skin fat stayed same—only deep dangerous fat melted. IGF-1 (the growth signal) jumped 108 ng/mL. Body image scores surged; men felt way better. Blood sugar stayed normal, no serious side effects beyond mild shot site reactions. This proves Tesamorelin's power for HIV lipodystrophy, improving looks and heart health long-term.

Study: Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
Benefits: Keeps belly fat off for a full year, maintains muscle and strength, steadies good cholesterol and blood fats.
Link: https://pubmed.ncbi.nlm.nih.gov/18690162/
Summary: After 26 weeks of work, 410 HIV patients kept going or switched to Tesamorelin for 26 more weeks. Those staying on it held their 18% belly fat loss strong at 52 weeks (35 cm² down). Triglycerides stayed dropped 51 mg/dL below start. Total cholesterol held lower. Glucose stayed stable—no diabetes risk even long-term. When patients quit, belly fat came back, proving the medicine keeps working while used but isn't permanent (like exercise). Safe profile matched first 6 months. For HIV folks stuck with extra gut weight, this shows Tesamorelin is a trusty, consistent fix for 12 months, reshaping body safely.

Study: Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity
Benefits: Shrinks waist, boosts growth hormone (IGF-1), improves thinking and mood hints in HIV brain fog.
Link: https://pubmed.ncbi.nlm.nih.gov/39813152/
Summary: 73 HIV patients with fuzzy thinking and big bellies took Tesamorelin 2mg daily or standard care for 6 months. Waist shrank 2.7 cm more with Tesamorelin; IGF-1 spiked, fueling cells. Thinking test scores trended better (+0.146 vs +0.103 for care-as-usual), but gap missed significance—likely study too small. Brain fog from belly fat and low growth hormone improved subtly, hinting at deeper brain benefits. Daily injection simple. Safe—no odd side hits. Shows Tesamorelin's promise beyond just fat loss, touching brain health tied to obesity in HIV survivors.

Study: Tesamorelin improves fat quality independent of changes in visceral adiposity (muscle quality and composition effects)
Benefits: Tones abdominal muscles, fills rectus/core lean tissue, strengthens trunk even without extra fat loss.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC6766405/
Summary: CT scans of 341 HIV patients on Tesamorelin showed core muscles got denser and firmer—rectus belly muscle jumped 4.86 Hounsfield units (density boost). Lean meat in abs, flanks, lower back all thickened. Muscle fat decreased separately from belly fat drop, meaning peptide rebuilds tone. Abs looked carved, waist lines sharper. Effects held even after adjusting for IGF-1 spikes, proving local muscle tighten. Perfect for folks wanting sculpted cores, not just thin bellies—Tesamorelin delivers gym-like toning via hormone magic.

Tesamorelin research spotlights belly-fat buster for HIV. Visceral fat melts 24%, muscle tones, cholesterol drops, mood lifts—safe a full year and beyond.

Tesamorelin stands out as a synthetic growth hormone-releasing hormone (GHRH) analog specifically engineered to combat visceral adipose tissue (VAT) accumulation, particularly in HIV patients experiencing lipodystrophy from antiretroviral therapy. By binding to pituitary GHRH receptors, it triggers pulsatile endogenous growth hormone (GH) secretion, elevating insulin-like growth factor-1 (IGF-1) levels that preferentially mobilize deep abdominal fat around organs while sparing subcutaneous fat. This targeted lipolysis yields 15-24% VAT reductions over 26-52 weeks, alongside improvements in triglycerides (down 37-51 mg/dL), cholesterol-to-HDL ratios, waist circumference (down 3.4 cm), and patient-reported body image distress. Even in modern regimens with integrase strand transfer inhibitors (INSTIs)—linked to weight gain—tesamorelin achieves 11.5% VAT drops and 3.2% trunk fat reductions without glycemic worsening or serious adverse events beyond mild injection-site reactions. Hepatic benefits emerge too, with ALT reductions of 7.4 U/L in responders, tying fat loss to better liver enzymes. Long-term data confirm sustained effects during treatment, though VAT rebounds upon discontinuation, emphasizing its role as maintenance therapy for metabolic dysregulation in HIV.

Study: Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
Benefits: Delivers 24% VAT reduction at 26 weeks (sustained 17.5% at 52 weeks), slashes triglycerides 37 mg/dL, enhances lipid profiles and belly appearance satisfaction without glucose shifts.
Link: https://pubmed.ncbi.nlm.nih.gov/20554713/
Summary: Pooled phase 3 data from 806 ART-treated HIV patients showed daily 2 mg subcutaneous tesamorelin shrinking VAT by 24% versus a 2% placebo increase at 26 weeks, with IGF-1 rising 108 ng/mL. Triglycerides dropped 37 mg/dL, cholesterol-to-HDL improved 0.31 units, and waistlines narrowed 3.4 cm by year one. Body image scores soared, driven by selective visceral targeting that preserved subcutaneous fat. Safety held firm—no meaningful glucose changes or malignancies—positioning tesamorelin as a transformative option for HAART-induced abdominal obesity, directly mitigating cardiovascular risks through fat redistribution and lipid optimization.

Study: Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
Benefits: Maintains 18% VAT loss and 51 mg/dL triglyceride cuts over 52 weeks, with stable cholesterol and no glucose intolerance progression.
Link: https://pubmed.ncbi.nlm.nih.gov/18690162/
Summary: In a 410-patient extension, continuous tesamorelin preserved 35 cm² VAT reductions and metabolic gains through week 52, while switchers from placebo gained benefits and continuous users avoided rebound during therapy. Adverse events mirrored early phases, underscoring long-term tolerability and the necessity of ongoing dosing to sustain lipolytic and lipid-lowering effects in chronic HIV lipodystrophy.

Study: Efficacy and safety of tesamorelin in people with HIV on integrase inhibitor-based regimens
Benefits: Counters INSTI weight gain with 11.5% VAT and 4.2% hepatic fat declines over 12 months, matching placebo on adverse events including hyperglycemia.
Link: https://pubmed.ncbi.nlm.nih.gov/38905488/
Summary: Among 38 INSTI users with steatotic liver disease, tesamorelin outperformed placebo in VAT (-25 cm² median vs. +14 cm²), hepatic fat (-4.2% vs. -0.5%), and trunk-to-appendicular fat ratio, proving efficacy amid contemporary ART challenges. Tolerability was equivalent, affirming its relevance for evolving HIV management where adiposity persists despite viral control.

Study: Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV
Benefits: VAT responders see ALT drops of 7.4 U/L persisting to 52 weeks, linking adiposity relief to hepatic health independent of full fat regain.
Link: https://pubmed.ncbi.nlm.nih.gov/28832410/
Summary: In patients with elevated transaminases, tesamorelin responders achieved meaningful ALT improvements over non-responders, sustained long-term and decoupled from complete VAT reversal. This mechanistic tie highlights tesamorelin's broader metabolic rescue beyond fat loss, addressing non-alcoholic fatty liver risks in HIV cohorts.

Tesamorelin's precision VAT targeting reshapes HIV-related body composition, delivering enduring metabolic and hepatic gains with proven safety across treatment eras—essential for those stalled by stubborn abdominal fat.

Tesamorelin – Research Links